STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more

The incoming Democratic chairs of key congressional committees are planning to investigate most-favored nation drug pricing agreements, which could potentially impact the pharmaceutical industry and healthcare costs in the U.S.

This move is part of a broader effort by Democrats to lower prescription drug prices and could have significant implications for the industry and consumers.

The investigation could also impact seafarers, as changes in the pharmaceutical industry may affect the availability and cost of medication on ships and at ports.